BioLife Solutions initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of BioLife Solutions with a Buy rating and $29 price target. BioLife is a pure-play supplier of tools and services for cell and gene therapies, the analyst tells investors in a research note. The firm says BioLife is a leading supplier of cell processing tools and biostorage services for cell and gene therapy and broader biopharma markets. It says the divestiture of the freezer business improves the company’s operational efficiency.